Paradigm Medical Industries to Introduce Early Glaucoma Detection Device at ASCRS Conference

SALT LAKE CITY--(BUSINESS WIRE)--Paradigm Medical Industries, Inc. (OTCBB: PMED.OB), said today it will introduce the Glaid-PERG electrophysiology instrument for the early detection of glaucoma at the American Society for Cataract Refractive Surgeons (ASCRS) Conference in Chicago, IL, next month.

“All research and studies indicate the Glaid-PERG diagnostic device is the earliest means of detecting cellular losses attributed to glaucoma and other ocular ailments,” said Paradigm Medical’s Chief Executive Officer, Raymond Cannefax. The Company signed an exclusive agreement with LACE Elettronica srl (Rome, Italy) to distribute the Glaid-PERG instrument earlier this year.

After many years of clinical studies at major U.S. and European glaucoma centers, as well as at universities and research centers, the Glaid-PERG has proven to provide high test repeatability and a high level of accuracy. Ongoing research is indicating testing application for ocular ailments other than glaucoma.

“We are excited about the impact the new instrument will have—not only in our industry, but in medical benefits to those who will be diagnosed early as glaucoma suspects,” Mr. Cannefax added. “Early diagnosis will help reduce vision loss and help preserve sight. This is a logical progression in the early detection of glaucoma, the world’s major contributor to vision loss.”

Paradigm Medical will also introduce the prototype version of its redesigned LD400 Autoperimetry system at the ASCRS show. The LD400 is used to measure patient visual fields to determine the severity of glaucoma and to aid in managing the disease.

“The introduction of these two devices is further indication of our Company’s leading technology in eye care,” Mr. Cannefax noted. “It is all part of our ‘Continuous Improvement’ commitment.”

Paradigm Medical Industries, Inc., is a leader in Ultrasound devices, and glaucoma detection and management products.

This press release contains statements that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events and outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainty and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.